Business Context and Reporting Period
Company: Repligen Corporation
Filing Type: Form 10-K (Annual Report)
Period Ended: March 31, 2004
Business Overview: Repligen develops novel biological products for neuropsychiatric disorders (schizophrenia, anxiety, bipolar disorder) and autoimmune diseases. The company funds its therapeutic development programs through profits from its specialty pharmaceutical products: recombinant Protein A (rProtein A) for antibody manufacturing and SecreFlo (diagnostic secretin).
Key Financial Metrics (Fiscal Year 2004)
| Metric | Value (in thousands) |
|---|---|
| Total Revenue | $6,914 |
| Cost of Revenue | $3,248 |
| Gross Profit | $3,666 |
| Gross Margin | 53% |
| Operating Expenses | $13,607 |
| Net Loss | $(9,551) |
| Net Loss Per Share | $(0.32) |
| Cash and Marketable Securities | $24,863 |
| Working Capital | $13,684 |
| Accumulated Deficit | $(154,507) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 11% to $6.9 million from $7.8 million in fiscal 2003. This was driven by a 26% drop in rProtein A sales ($5.0M vs $6.7M) due to customer manufacturing issues and regulatory timing, partially offset by an 86% increase in SecreFlo sales ($1.9M vs $1.0M).
- Increased Operating Loss: Net loss widened to $9.6 million from $4.5 million. This was primarily due to a $2.4 million non-cash impairment charge related to the SecreFlo license agreement and a 24% increase in R&D expenses to $6.5 million.
- Liquidity Position: Cash and marketable securities increased to $24.9 million from $18.9 million, bolstered by a $11.8 million net proceeds from a common stock offering in May 2003.
Outlook, Risks, and Contingencies
Management Commentary and Outlook
Management expects to continue incurring operating losses for the foreseeable future as it invests in clinical trials. The company anticipates expenses in fiscal 2005 to be similar to fiscal 2004, excluding the one-time impairment charge. Repligen believes it has sufficient resources to meet working capital needs for the next 24 months.
Material Risks and Contingencies
- SecreFlo Supply Dispute (Critical): In February 2004, Repligen terminated its licensing agreement with ChiRhoClin, its sole supplier of SecreFlo, alleging breach of contract. ChiRhoClin disputed this termination in June 2004 and requested Repligen stop marketing the product. Repligen recorded a $2.4 million impairment charge reflecting the risk that future sales will be limited to current inventory. Repligen is seeking to recover approximately $5 million in prior payments.
- Patent Litigation:
- Bristol-Myers Squibb: Repligen is appealing a District Court ruling that denied its claim to inventorship of certain CTLA4 patents. Failure to obtain these rights could restrict commercialization of CTLA4-Ig.
- ImClone Systems: Repligen and MIT have sued ImClone for patent infringement regarding the Erbitux cancer drug.
- Pro-Neuron: A settlement is pending regarding uridine patent rights, which would exclude Repligen from the acylated pyrimidine field but allow continued trials in bipolar disorder.
- Capital Requirements: The company requires additional long-term financing to complete clinical trials and may need to raise capital through debt or equity, which could be difficult given market volatility.
Investor Verification Checklist
- SecreFlo Arbitration Status: Verify the current status of the arbitration with ChiRhoClin and the likelihood of continued product supply.
- Impairment Charge Validity: Confirm the assumptions used for the $2.4 million impairment charge regarding the SecreFlo license.
- Cash Burn Rate: Assess the runway of the $24.9 million cash balance against the projected $11-12 million annual operating burn (excluding impairment).
- Patent Litigation Outcomes: Monitor the Federal Circuit appeal regarding the Bristol-Myers Squibb CTLA4 patents, as this is critical for the autoimmune pipeline.
- rProtein A Customer Concentration: Review the impact of the manufacturing issues at major customers (Amersham Biosciences, Cardinal Healthcare) on future revenue stability.